Next Article in Journal
Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [18F]PSS232 in the Rat Brain
Next Article in Special Issue
Modulation of Iron Metabolism in Response to Infection: Twists for All Tastes
Previous Article in Journal
A Novel Protocol Using Small-Scale Spray-Drying for the Efficient Screening of Solid Dispersions in Early Drug Development and Formulation, as a Straight Pathway from Screening to Manufacturing Stages
Previous Article in Special Issue
Iron Release from Soybean Seed Ferritin Induced by Cinnamic Acid Derivatives
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Pharmaceuticals 2018, 11(3), 82; https://doi.org/10.3390/ph11030082

Intravenous Irons: From Basic Science to Clinical Practice

1
Hull and East Yorkshire Hospitals NHS Trust and Hull York Medical School, Hull HU3 2JZ, UK
2
Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK
3
MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, Gambia
4
School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK
5
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Headington, Oxford OX3 9DS, UK
6
Haematology Theme Oxford Biomedical Research Centre, Oxford OX3 9DS, UK
*
Author to whom correspondence should be addressed.
Received: 1 August 2018 / Revised: 22 August 2018 / Accepted: 23 August 2018 / Published: 27 August 2018
(This article belongs to the Special Issue Iron as Therapeutic Targets in Human Diseases)
Full-Text   |   PDF [1673 KB, uploaded 28 August 2018]   |  

Abstract

Iron is an essential trace mineral necessary for life, and iron deficiency anaemia (IDA) is one of the most common haematological problems worldwide, affecting a sixth of the global population. Principally linked to poverty, malnutrition and infection in developing countries, in Western countries the pathophysiology of IDA is primarily linked to blood loss, malabsorption and chronic disease. Oral iron replacement therapy is a simple, inexpensive treatment, but is limited by gastrointestinal side effects that are not inconsequential to some patients and are of minimal efficacy in others. Third generation intravenous (IV) iron therapies allow rapid and complete replacement dosing without the toxicity issues inherent with older iron preparations. Their characteristic, strongly-bound iron-carbohydrate complexes exist as colloidal suspensions of iron oxide nanoparticles with a polynuclear Fe(III)-oxyhydroxide/oxide core surrounded by a carbohydrate ligand. The physicochemical differences between the IV irons include mineral composition, crystalline structure, conformation, size and molecular weight, but the most important difference is the carbohydrate ligand, which influences complex stability, iron release and immunogenicity, and which is a unique feature of each drug. Recent studies have highlighted different adverse event profiles associated with third-generation IV irons that reflect their different structures. The increasing clinical evidence base has allayed safety concerns linked to older IV irons and widened their clinical use. This review considers the properties of the different IV irons, and how differences might impact current and future clinical practice. View Full-Text
Keywords: adverse event profile; anaemia; bioengineering; labile iron; intravenous iron; iron-carbohydrate complex; iron processing adverse event profile; anaemia; bioengineering; labile iron; intravenous iron; iron-carbohydrate complex; iron processing
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Bhandari, S.; Pereira, D.I.A.; Chappell, H.F.; Drakesmith, H. Intravenous Irons: From Basic Science to Clinical Practice. Pharmaceuticals 2018, 11, 82.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top